![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » TEVA RELEASES ADDITIONAL DATA ON PARKINSON'S TREATMENT
TEVA RELEASES ADDITIONAL DATA ON PARKINSON'S TREATMENT
Israeli drugmaker Teva has presented new data on its drug Azilect (rasagiline tablets) as initial monotherapy for Parkinson's disease, as first adjunctive therapy in moderate Parkinson's and in combination with other adjunct agents in moderate to advanced Parkinson's. The data was obtained through further analysis of the three clinical studies in more than 1,500 patients that supported the approval of the drug for the symptomatic treatment of Parkinson's disease.
For example, in trials with Azilect as an initial monotherapy, patients maintained their quality-of-life scores while scores deteriorated in the placebo group. Additionally, analysis of Azilect as adjunct therapy in addition to levodopa showed that the combination produced additional symptomatic benefits.
Azilect is currently indicated for the treatment of the signs and symptoms of Parkinson's disease both as initial therapy alone and to be added to levodopa later in the disease. Symptoms of Parkinson's include tremor, stiffness, slowness of movement and impaired balance.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct